BofA analyst Tazeen Ahmad raised the firm’s price target on Ascendis Pharma (ASND) to $242 from $230 and keeps a Buy rating on the shares. The firm’s survey of 26 endocrinologists who treat HPT patients on Yorvipath indicates growing uptake in Q3, says the analyst, who is “encouraged” by the continued positive real-world outlook for Yorvipath usage and looks for updated commentary from the company on payor coverage and trending discontinuation rate on the earnings call.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma’s Promising Growth: Yorvipath Uptake and Anticipated TransCon CNP Approval Drive Buy Rating
- Ascendis Pharma initiated with a Strong Buy at Raymond James
- Ascendis Pharma Grants Employee Warrants to Boost Engagement
- Ascendis Pharma price target raised to $254 from $203 at Cantor Fitzgerald
- Ascendis Pharma Submits EMA Application for Achondroplasia Treatment